Project Grant R21AI193250
- Federal Grant Award Summary Yale University received a $662,465 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) on February 6, 2026, with an ultimate completion date of January 31, 2031. This research initiative, titled "Durable and Broad Airway Immunity Through Next-Generation Intranasal Boosters," focuses on developing and understanding next-generation mucosal...
- Federal Project Grant Award Summary Yale University received a $792,513 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded April 8, 2026, with a completion date of March 31, 2031. The award funds research addressing serotype re-emergence and vaccine impact in the context of next-generation pneumococcal conjugate vaccines (PCVs). The research delivers novel scientific insights...
- Federal Grant Award Summary Yale University received a $735,631 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded April 1, 2026, with completion targeted for March 31, 2031. The research focuses on investigating the origin and functional properties of CX3CR1+ neutrophils, a novel neutrophil population with distinct biological characteristics compared to canonical neutrophils....
- Federal Project Grant Award Summary Yale University received a $405,585 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded on July 18, 2025, with completion targeted for June 30, 2027. The grant supports the development of a multiplexed CRISPR activation and interference (CRISPRa/i) system designed to elucidate gene regulatory networks underlying T cell development in primary...
- Federal Project Grant Award Summary Yale University received a $251,563 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), with an award date of February 20, 2026 and completion date of January 31, 2028. The research deliverables include a comprehensive longitudinal cohort study assessing the immunogenicity of QDENGA (Takeda's TAK-003) dengue vaccine in 110 participants tracked from...
- Federal Grant Award Summary Yale University received a $373,090 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded August 25, 2025, with a completion date of July 31, 2026. The award supports development of Modular Degraders of Extracellular Proteins (MODES), a novel therapeutic approach designed to remove pathogenic extracellular proteins from circulation. The research program...
- Federal Grant Award Summary Yale University received a $453,629 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded July 8, 2025, with completion targeted for June 30, 2027. The grant supports development and application of PHAGE-SEQ, a high-throughput technology combining phage display of nanobodies (VHH recognition domains derived from camelid heavy chain-only immunoglobulins)...
- Federal Grant Award Summary Yale University received a $603,338 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) effective July 3, 2025, with a completion date of June 30, 2030. The award supports advanced structural and computational research investigating human immunodeficiency virus 1 (HIV-1) fusion mechanisms on native cell membranes. The primary deliverables include...
- Federal Project Grant Award Summary Yale University received a $778,828 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded April 6, 2026, with a completion date of March 31, 2031. This award supports investigator-initiated research examining novel loss-of-function gene variants in ZFYVE21 and their role in dysregulated innate immunity. The research deliverables include...
- Federal Project Grant Award Summary Yale University received a $105,402 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) effective September 27, 2026, with a completion date of April 15, 2029. The award supports investigator-initiated biomedical research focused on understanding the mechanisms of resilience to cytokinopathy flares in autoinflammatory diseases. The research addresses...
Yale University received a $251,938 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded June 12, 2026, with completion targeted for May 31, 2028. The award funds research to discover and develop cell-intrinsic immunologic adjuvants designed to enhance next-generation self-amplifying RNA (saRNA) vaccines. The primary deliverable is investigation of novel molecular approaches that co-express vaccine antigens (SARS-CoV-2 spike and influenza A virus H5N1 hemagglutinin) with immunomodulatory molecules on a single RNA molecule, addressing limitations of current messenger RNA (mRNA) lipid nanoparticle vaccines including reactogenicity, high dose requirements, and limited immune response durability. The research encompasses two specific aims: assessment of saRNA-antigen/immunomodulator co-expression delivered as lipid nanoparticle formulations (Aim 1) and co-formulated mRNA-antigen plus mRNA-immunomodulator approaches (Aim 2), with evaluation of key dendritic cell licensing and trafficking molecules including CD40, CD80, CCR7, and T-bet. Measurable outputs include characterization of antibody potency, breadth, durability, and safety/reactogenicity profiles. The investigation is intended to produce foundational scientific knowledge and preclinical data supporting development of improved nucleic acid vaccines with enhanced efficacy at lower doses while minimizing toxicity associated with molecularly encoded cytokine adjuvants.Federal Project Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $251.9k | 6/16/26 |